Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative products that address unmet medical needs, primarily focusing on orally administered therapies. The company's mission is to advance medicines through innovative science and delivery technologies to bring meaningful improvements to patients' lives by offering more practical medication solutions. Headquartered in Warren, New Jersey, Aquestive leverages its proprietary platforms to transform drug delivery.

Central to Aquestive's product development are its proprietary PharmFilm® technology, which enables the delivery of drugs via thin, dissolvable oral films, and AdrenaVerse™, a novel prodrug platform. The company's commercialized portfolio, marketed by licensees globally, includes Sympazan® (clobazam) for Lennox-Gastaut Syndrome, Exservan™ (riluzole) for Amyotrophic Lateral Sclerosis (ALS), Suboxone®, Emylif®, and Ondif®. Aquestive also maintains a robust pipeline, with late-stage candidates such as Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis, and Libervant® (diazepam) buccal film for seizure clusters.

In recent news, Aquestive Therapeutics completed a Type A meeting with the FDA for its Anaphylm™ (dibutepinephrine) Sublingual Film and plans to resubmit its New Drug Application (NDA) in the third quarter of 2026. The company also intends to submit regulatory applications for Anaphylm in Canada and the European Union in 2026. Leadership includes Daniel Barber as President and CEO, supported by recent executive appointments such as Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, and an expanded team to support growth initiatives. Aquestive positions itself as a leader in providing patient-friendly alternatives to invasive and inconvenient standard-of-care therapies.